The results of this study identify about 25% of urothelial carcinomas of the urinary bladder as MTAP‐deficient and demonstrate that MTAP deficiency goes along with a noninflamed tumor microenvironment, aggressive tumor phenotype, and poor patient prognosis in muscle‐invasive disease. This evidence concerns the gene MTAP and bladder transitional cell carcinoma.